首页> Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association> Tumor mutation burden is correlated with response and prognosis in microsatellite-stable (MSS) gastric cancer patients undergoing neoadjuvant chemotherapy.

Tumor mutation burden is correlated with response and prognosis in microsatellite-stable (MSS) gastric cancer patients undergoing neoadjuvant chemotherapy.

导出原文传递

翻译打印收藏纠错

第一作者： Ziyu,Li

第一单位： Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Surgery, Peking University Cancer Hospital and Institute, Beijing, 100142, China.

作者： Ziyu,Li ^[1] ; Yongning,Jia ^[1] ; Honglin,Zhu ^[2] ; Xiaofang,Xing ^[3] ; Fei,Pang ^[1] ; Fei,Shan ^[1] ; Shuangxi,Li ^[1] ; Danhua,Wang ^[2] ; Fangping,Zhao ^[2] ; Tonghui,Ma ^[2] ; Sizhen,Wang ^[2] ; Jiafu,Ji ^[4]

作者单位： Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Surgery, Peking University Cancer Hospital and Institute, Beijing, 100142, China. ^[1] Genetron Health (Beijing) Technology, Co. Ltd, Beijing, 102206, China. ^[2] Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Center for Molecular Diagnostics, Peking University Cancer Hospital and Institute, Beijing, 100142, China. ^[3] Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Surgery, Peking University Cancer Hospital and Institute, Beijing, 100142, China. jijiafu@hsc.pku.edu.cn. ^[4]

关键词 Microsatellite stability (MSS)Neoadjuvant chemotherapy Tumor mutation burden (TMB)